Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Portable Device Finds Sepsis Infection Markers

By LabMedica International staff writers
Posted on 20 Jul 2017
A new portable device can quickly find markers of deadly, unpredictable sepsis infection from a single drop of blood, which is the first to provide rapid, point-of-care measurement of the immune system's response, without any need to process the blood.

Sepsis is routinely detected by monitoring patients' vital signs, such as blood pressure, oxygen levels, temperature and others. More...
If a patient shows signs of being septic, the doctors try to identify the source of the infection with blood cultures and other tests that can take days, time the patient may not have. The new device takes a different approach.

Scientists at the University of Illinois at Urbana-Champaign (Urbana, IL, USA) and their colleagues tested the device with blood samples from patients in the intensive care unit (ICU) and emergency room. When a physician suspected infection and ordered a blood test, a small drop of the blood drawn was given to the team, stripped of identifying information to preserve patient confidentiality. The team was able to monitor CD64 levels over time, correlating them with the patient's vital signs. They found that the results from the rapid test correlated well with the results from the traditional tests and with the patients' vital signs. The small, lab-on-a-chip device counts white blood cells in total as well as specific white blood cells called neutrophils, and measures a protein marker called CD64 on the surface of neutrophils. The levels of CD64 surge as the patient's immune response increases.

Rashid Bashir, PhD, a professor of bioengineering and lead investigator, said, “We are looking at the immune response, rather than focusing on identifying the source of the infection. One person's immune system might respond differently from somebody else's to the same infection. In some cases, the immune system will respond before the infection is detectable. This test can complement bacterial detection and identification. We think we need both approaches: detect the pathogen, but also monitor the immune response.”

The team is working to incorporate measurements for other inflammation markers into the rapid-testing device to give a more complete picture of the body's response, and to enable earlier detection. They also have a startup company, Prenosis Inc (Champaign, IL, USA) that is working to commercialize the device. The study was published on July 3, 2017, in the journal Nature Communications.

Related Links:
University of Illinois at Urbana-Champaign
Prenosis

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.